Post-translational modification and stability of low molecular weight cyclin e

Oncogene

Volumn 28, Issue 35, 2009, Pages 3167-3176

  Mull, B B ^a,b   Cox, J ^a   Bui, T ^a   Keyomarsi, K ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Cell cycle; Cyclin E; Low molecular weight form; Phosphorylation; Stability

Indexed keywords

ALANINE; CYCLIN E; ELASTASE; ISOPROTEIN; THREONINE;

ARTICLE; BREAST EPITHELIUM; CONTROLLED STUDY; ENZYME ACTIVITY; EPITHELIUM CELL; HUMAN; HUMAN CELL; MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; PROTEIN STABILITY; SITE DIRECTED MUTAGENESIS; TUMOR CELL LINE;

ALANINE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BREAST NEOPLASMS; CELL LINE; CELL LINE, TUMOR; CYCLIN E; CYCLIN-DEPENDENT KINASE 2; CYCLIN-DEPENDENT KINASE INHIBITOR P27; HUMANS; KIDNEY; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MOLECULAR WEIGHT; P21-ACTIVATED KINASES; PHOSPHORYLATION; PROTAMINE KINASE; PROTEIN BINDING; PROTEIN ISOFORMS; PROTEIN PROCESSING, POST-TRANSLATIONAL; TRANSFECTION;

EID: 69849083726     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.182     Document Type: Article

References (29)

1. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D et al. (2007). Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res 67: 7212-7222.
2. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N et al. (2004). Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res 64: 3198-3208.
3. Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D et al. (2005). The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res 65: 692-697.
4. Clurman BE, Sheaff RJ, Thress K, Groudine M, Roberts JM. (1996). Turnover of cyclin E by the ubiquitin-proteosome pathway is regulated by cdk2 binding and cyclin phosphorylation. Genes & Dev 10: 1979-1990.
5. Delk NA, Hunt KK, Keyomarsi K. (2009). Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. Cancer Res 69: 2817-2825.
6. Harwell RM, Porter DC, Danes C, Keyomarsi K. (2000). Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 60: 481-489.
7. Honda R, Lowe ED, Dubinina E, Skamnaki V, Cook A, Brown NR et al. (2005). The structure of cyclin E1/CDK2: implications for CDK2 activation and CDK2-independent roles. EMBO J 24: 452-463.
8. Hwang HC, Clurman BE. (2005). Cyclin E in normal and neoplastic cell cycles. Oncogene 24: 2776-2786.
9. Karsunky H, Geisen C, Schmidt T, Haas K, Zevnik B, Gau E et al. (1999). Oncogenic potential of cyclin E in T-cell lymphomagenesis in transgenic mice: evidence for cooperation between cyclin E and Ras but not Myc. Oncogene 18: 7816-7824.
10. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. (1994). Cyclin E, a potential prognostic marker for breast cancer. Cancer Res 54: 380-385.
11. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN et al. (2002). Cyclin E and survival in patients with breast cancer. N Engl J Med 347: 1566-1575.
12. Libertini SJ, Robinson BS, Dhillon NK, Glick D, George M, Dandekar S et al. (2005). Cyclin E both regulates and is regulated by calpain 2, a protease associated with metastatic breast cancer phenotype. Cancer Res 65: 10700-10708.
13. Loeb KR, Kostner H, Firpo E, Norwood T, D Tsuchiya K, Clurman BE et al. (2005). A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell 8: 35-47.
14. Minella AC, Loeb KR, Knecht A, Welcker M, Varnum-Finney BJ, Bernstein ID et al. (2008). Cyclin E phosphorylation regulates cell proliferation in hematopoietic and epithelial lineages in vivo. Genes Dev 22: 1677-1689.
15. Minella AC, Swanger J, Bryant E, Welcker M, Hwang H, Clurman BE. (2002). p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol 12: 1817-1827.
16. Nguyen HH, Aronchik I, Brar GA, Nguyen DH, Bjeldanes LF, Firestone GL. (2008). The dietary phytochemical indole-3-carbinol is a natural elastase enzymatic inhibitor that disrupts cyclin E protein processing. Proc Natl Acad Sci USA 105: 19750-19755.
17. Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S et al. (2001). Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol 21: 6254-6269.
18. Porter PL, Malone KE, Heagerty PJ, Alexander GM, Gatti LA, Firpo EJ et al. (1997). Expression of cell-cycle regulators p27Kip1 and cyclin E, alone and in combination, correlate with survival in young breast cancer patients. Nat Med 3: 222-225.
19. Smith AP, Henze M, Lee JA, Osborn KG, Keck JM, Tedesco D et al. (2006). Deregulated cyclin E promotes p53 loss of heterozygosity and tumorigenesis in the mouse mammary gland. Oncogene 25: 7245-7259.
20. Spruck CH, Won KA, Reed SI. (1999). Deregulated cyclin E induces chromosome instability. Nature 401: 297-300.
21. Strohmaier H, Spruck CH, Kaiser P, Won KA, Sangfelt O, Reed SI. (2001). Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line. Nature 413: 316-322.
22. Welcker M, Clurman BE. (2007). Fbw7/hCDC4 dimerization regulates its substrate interactions. Cell Div 2: 7.
23. Welcker M, Clurman BE. (2008). FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer 8: 83-93.
24. Welcker M, Singer J, Loeb KR, Grim J, Bloecher A, Gurien-West M et al. (2003). Multisite phosphorylation by Cdk2 and GSK3 controls cyclin E degradation. Mol Cell 12: 381-392.
25. Wingate H, Bedrosian I, Akli S, Keyomarsi K. (2003). The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle 2: 461-466.
26. Wingate H, Puskas A, Duong M, Bui T, Richardson D, Liu Y et al. (2009). Tumor specific in breast cancer and tumorigenic in human mammary epithelial cells. Cell Cycle 8: 1062-1068.
27. Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. (2005). The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem 280: 15148-15157.
28. Won K-A, Reed SI. (1996). Activation of cyclin E/cdk2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. EMBO J 15: 4182-4193.
29. Ye X, Nalepa G, Welcker M, Kessler BM, Spooner E, Qin J et al. (2004). Recognition of phosphodegron motifs in human cyclin E by the SCF(Fbw7) ubiquitin ligase. J Biol Chem 279: 50110-50119.